Deep Brain Hacking Goes Wearable

A British startup says it can reach deep inside your brain and change how it fires, all without cutting the skin.

Quick Take

NeuroHarmonics rebranded around the tagline “Redefining brain health, precisely,” built on a wearable ultrasound device.
The company says its device sends low-intensity sound waves through the skull to a target just millimeters wide.
Chief Executive Officer Bradley Treeby, a former biomedical ultrasound professor at University College London, co-founded the company to move the technology from hospitals into homes.
Outside medical research backs the general science of focused ultrasound but still calls the field early-stage.

A New Pitch for an Old Problem

NeuroHarmonics wants to change how doctors treat brain disorders. Its homepage promises “no incision, no implant, and no hair preparation” for a condition that once meant surgery. The company builds a wearable headset that aims sound waves at a precise spot deep in the brain. That pitch matters because current treatments for things like tremors or depression often require opening the skull or wearing bulky lab equipment.

The company says the mechanical pressure from these sound waves changes how easily neurons fire. That effect, it claims, is both immediate and reversible. No cutting, no wires left behind, no shaved head before treatment. If the claim holds up in wider use, it would mark a real shift in how brain conditions get managed day to day, not just in a hospital but potentially at home.

How the Technology Works

The device relies on transcranial focused ultrasound. Sound waves pass through the intact skull and converge on a target only a few millimeters wide. NeuroHarmonics describes this as “millimetre-scale focus,” aiming at deep brain structures that are normally hard to reach without surgery. The company frames this precision as its core advantage over older brain-stimulation tools.

Speedinvest, one of the company’s backers, describes the goal even more directly: pairing “surgical-level precision” with “at-home accessibility.” That combination is the entire business case. Doctors get a tool that reaches deep brain circuits. Patients get a headset instead of an operating room. Whether that promise scales beyond early testing is the next chapter for the company to write.

From Lab Bench to Living Room

NeuroHarmonics did not start as a consumer company. Its founders trace the technology back to academic research on biomedical ultrasound. Treeby spent his career studying the field at University College London before turning that research into a commercial product. The company’s own blog calls this the journey “from academia to co-founding NeuroHarmonics.”

That path from lab whiteboard to wearable device is common in neurotech, but it still takes years. Speedinvest, which backed the company alongside University College London’s technology fund, says its investment reflects “conviction in the potential of non-invasive neuromodulation.” Investors are betting the science will catch up to the marketing.

The Bigger Picture in Neurotech

Transcranial focused ultrasound is not a NeuroHarmonics invention. Medical researchers have studied it for years as a way to reach deep brain regions without surgery. A safety review published in a peer-reviewed neuroscience journal found the technique has “exquisite spatial specificity” and rarely causes side effects in the studies reviewed so far.

A more recent review calls transcranial focused ultrasound an “emerging” technique with “significant potential” for treating neurological disorders. That word, emerging, matters. It means the science shows real promise, but it also means large-scale, long-term human studies are still being built out across the field, not just at one company.

What the Science Says So Far

A separate systematic review looking specifically at safety found that adverse effects from transcranial focused ultrasound were “very rare” across the human and animal studies it examined. That is a reassuring data point for a technology aimed at something as sensitive as the human brain.

None of this means every claim a company makes about its own device is automatically proven. It means the underlying science has real support in the research world, which is exactly the kind of foundation a serious brain-health company should be building on. For patients watching this space, that distinction is worth remembering.

What happens next will likely depend on clinical results, not press releases. NeuroHarmonics has laid out a bold vision: a wearable device that treats the brain with surgical precision but none of the surgery. The broader research community has laid the groundwork showing that idea is not far-fetched. Turning both into an everyday medical reality is the work still ahead.